US Government as Represented by the Secretary of the Army

John E Van Hamont

Jean A Setterstrom

Robert H Reid

Charles E McQueen

Curt Thies

F Donald Roberts

Phil Friden

Thomas R Tice

Edgar C Boedeker

Elliot Jacob

William R Brown

Frederick J Cassels

Daniel L Jarboe

Noelle Christine Vook

Elliott Jacob

William Vaughan

Ha Duong

Ramasubbu Jeyanthi

Thomas C Van Cott

Paul R Burnett

Jerald C Sadoff

Alan S Cross

Apurba K Bhattacharjee

Wendell David Zollinger

Ramasubbu Jevanthi

William M Vaughn

William M Vaugn

Egar C Boedeker

Edgar C Boedecker

Debrah L Birx

Ramassubbu Jeyanthi

Deborah L Birx

This invention relates to parenteral and mucosal vaccines against diseases caused by intercellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1&#x2013;100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.

'Burst-free' sustained release poly-(lactide/glycolide) microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.

Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix

A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophobic bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).

Sustained release hydrophobic bioactive PLGA microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.

Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix

A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a non-steroidal, antiinflammatory drug over a duration from 24 hours to 2 months, comprising: a non-steroidal, antiinflammatory drug and a blend of biocompatible, biodegradable poly (lactide/glycolide).

Sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophocib bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

This invention relates to parenteral and mucosal vaccines against diseases aused by intracellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Vaccines against intracellular pathogens using antigens encapsulated

A hybrid evaporation-extraction process for preparing microspheres of a p(DL-lactide-to-glycolide) biodegradable polymer, comprising:

Extraction process for producing PLGA microspheres

In a solvent extraction process for preparing microspheres of a biodegrade polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent to the polymer; adding the biodegradable polymer solution to the antigen-sucrose solution; adding an oil to the polymer-sucrose-antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers; centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 7.0 micrometers. An immunostimulating composition comprising an encapsulating-microsphere of the biodegradable polymer has an average particle size distribution such that the majority of the microspheres will be taken up by the villous epithelium section of the intestines of a mammalian subject when administered as a vaccine against diseases caused by enteropathogenic organisms.

Microparticle carriers of maximal uptake capacity by both M cells and

This invention is directed to oral parenteral and intestinal vaccines and eir use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

Growing community of inventors

Fort Meade, MD, United States of America

John E Van Hamont